生殖医療フロントラインMOOK（3）がん・生殖医療　がんサバイバーシップ向上を志向して

出版社： 中外医学社
著者：
発行日： 2023-05-15
分野： 臨床医学：外科  >  産婦人科学
ISBN： 9784498160446
電子書籍版： 2023-05-15 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

6,380 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

6,380 円(税込)

購入する

商品紹介

最前線の知識を学ぶ生殖医療シリーズ第三弾．がん患者の妊孕性の問題を多角的に解説．
生殖医療の最前線の知識と技術を伝えるシリーズ第三弾．がん患者の生存率の増加が著しい昨今，生殖医療はもはやマイナーな問題ではなく，重要なトピックの一つである．本書では，チーム全体で共有しておきたい基礎知識から最新の知見までを網羅した．執筆陣には医師のみならず，がん患者のサポートを行うコミュニティの代表なども参加．「がんサバイバーシップ向上」をキーワードに，多角的にがんと生殖医療を学べる１冊である．

目次

  • Chapter I　がん・生殖医療とは
    ［1］がん・生殖医療とは
    ［2］がんサバイバーシップ
    ［3］意思決定支援
    ［4］造血器腫瘍とがん・生殖医療
    ［5］小児とがん・生殖医療
    ［6］乳腺腫瘍とがん・生殖医療
    ［7］骨・軟部腫瘍とがん・生殖医療
    ［8］ASCO guideline 2018 Summary
    ［9］欧州の妊孕性温存に関するガイドライン2020年版について（ESMOならびにESHRE）
    ［10］日本癌治療学会ガイドライン
    ［11］ヘルスケアプロバイダーの役割

    Chapter II　妊孕性温存療法
    ［1］胚（受精卵）
    ［2］未受精卵子
    ［3］ランダムスタート法調節卵巣刺激
    ［4］AI併用卵巣刺激
    ［5］DuoStim法
    ［6］Onco-IVM
    ［7］卵巣組織
    ［8］GnRHによる卵巣保護
    ［9］精子（TESEも含む）
    ［10］精巣組織凍結

    Chapter III　がん・生殖医療の課題と展望
    ［1］ピアサポート（女性）
    ［2］がん・生殖ピアサポート（男性）
    ［3］オンコ・ウィメンズヘルスケア
    ［4］プレコンセプションケア
    ［5］里親・特別養子縁組
    ［6］医療連携（全国）
    ［7］移行期医療
    ［8］登録制度―日本がん・生殖医療登録システム（JOFR）の現状と課題
    ［9］公的助成金制度
    ［10］がん・生殖医療の今後の展望

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Chapter I がん・生殖医療とは

P.5 掲載の参考文献
1) Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2009; 27: 2677-85.
 
2) Levine JM, Whitton JA, Ginsberg JP, et al. Nonsurgical premature menopause and reproduc-tive implications in survivors of childhood cancer: a report from the Childhood Cancer Survi-vor Study. Cancer. 2018; 124: 1044-52.
 
3) Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010; 28: 332-9.
 
4) Schover LR, Rybicki LA, Martin BA, et al. Having children after cancer. A pilot survey of survi-vors' attitudes and experiences. Cancer. 1999; 86: 697-709.
 
5) Carter J, Rowland K, Chi D, et al. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol Oncol. 2005; 97: 90-5.
 
6) Green D, Galvin H, Horne B. The psycho-social impact of infertility on young male cancer sur-vivors: a qualitative investigation. Psychooncology. 2003; 12: 141-52.
 
7) Greer JA, Solis JM, Temel JS, et al. Anxiety disorders in long-term survivors of adult cancers. Psychosomatics. 2011; 52: 417-23.
 
8) Lu D, Andersson TM, Fall K, et al. Clinical diagnosis of mental disorders immediately before and after cancer diagnosis: a nationwide matched cohort study in Sweden. JAMA Oncol. 2016; 2: 1188-96.
 
9) Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopre-served ovarian tissue. Lancet. 2004; 364: 1405-10.
 
10) Waimey KE, Duncan FE, Su HI, et al. Future directions in oncofertility and fertility preservation: a report from the 2011 Oncofertility Consortium Conference. J Adolesc Young Adult Oncol. 2013; 2: 25-30
 
P.11 掲載の参考文献
1) 国立がん研究センター. がん情報サービス 集計表ダウンロード. 3. 生存率 https://ganjoho.jp/reg_stat/statistics/data/dl/index.html#anchor3
 
2) Ito Y, Miyashiro I, Ito H, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci. 2014; 105: 1480-6.
 
3) National Coalition for Cancer Survivorship. https://canceradvocacy.org/about/our-mission/
 
4) Institute of Medicine and National Research Council. Committee on Cancer Survivorship: Improving Care and Quality of Life National Cancer Policy Board. In: Hewitt M, et al. editors. From cancer patient to cancer survivor: Lost in transition. Washington, D. C.: The National Academies Press; 2006.
 
5) Jefford M, Rowland J, Grunfeld E, et al. Implementing improved post-treatment care for can-cer survivors in England, with reflections from Australia, Canada and the USA. Br J Cancer. 2013; 108: 14-20.
 
6) Cancer Net(R). What is Survivorship? https://www.cancer.net/survivorship/what-survivorship
 
7) Mullan F. Seasons of survival: reflections of a physician with cancer. N Engl J Med. 1985; 313: 270-3.
 
8) 厚生労働省. がん対策推進基本計画. 2018. https://www.mhlw.go.jp/content/10901000/000881207.pdf
 
9) Mayer DK, Nekhlyudov L, Snyder CF, et al. American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning. J Oncol Pract. 2014; 6: 345-51.
 
10) Beaver K, Luker KA. Follow-up in breast cancer clinics: reassuring for patients rather than detecting recurrence. Psychooncology. 2005; 14: 94-101.
 
11) Takahashi M. Cancer survivorship: current status of research, care, and policy in. Japan. Can-cer survivorship. Jpn J Clin Oncol. 2016; 46: 599-604.
 
12) Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study. J Natl Cancer Inst. 2008; 100: 1368-79.
 
13) Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 309: 2371-81.
 
14) Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood can-cer: a summary from the childhood cancer survivor study. J Clin Oncol. 2009; 27: 2328-38.
 
15) Chao C, Bhatia S, Xu L, et al. Chronic comorbidities among survivors of adolescent and young adult cancer. J Clin Oncol. 2020; 38: 3161-74.
 
16) Bright CJ, Reulen RC, Winter DL, et al. Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study) : a population-based, cohort study. Lancet Oncol. 2019; 20: 531-45.
 
17) Shimizu C, Bando H, Kato T, et al. Physicians' knowledge, attitude, and behavior regarding fer-tility issues for young breast cancer patients: a national survey for breast care specialists. Breast Cancer. 2013; 20: 230-40.
 
P.18 掲載の参考文献
1) Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004; 22: 4174-83.
 
2) Letourneau JM, Ebbel EE, Katz PP, et al. Pretreatment fertility counseling and fertility preser-vation improve quality of life in reproductive age women with cancer. Cancer. 2012; 118: 1710-7.
 
3) Lee RJ, Wakefield A, Foy S, et al. Facilitating reproductive choices: the impact of health ser-vices on the experiences of young women with breast cancer. Psycho-Oncology. 2011; 20: 1044-52.
 
4) Benedict C, Thom B, Friedman DN, et al. Young adult female cancer survivors' unmet informa-tion needs and reproductive concerns contribute to decisional conflict regarding posttreat-ment fertility preservation. Cancer. 2016; 122: 2101-9.
 
5) 日本癌治療学会. 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン. 東京: 金原出版; 2017.
 
6) Koizumi T, Nara K, Hashimoto T, et al. Influence of negative emotional expressions on the out-comes of shared decision making during oncofertility consultations in Japan. J Adolesc Young Adult Oncol. 2018; 7: 504-8.
 
7) 杉本公平. がん・生殖医療における情報提供と意思決定の支援. 日産婦会誌. 2018; 70: 1297-303.
 
8) 中山和弘, 岩本 貴. 患者中心の意思決定支援: 納得して決めるためのケア. 東京; 中央法規出版; 2012.
 
9) 杉森裕樹. がん・生殖医療におけるシェアード・ディシジョン・メイキング. 産婦の実際. 2015; 64: 1039-46.
 
10) Kim J, Mersereau JE. Early referral makes the decision-making about fertility preservation eas-ier: a pilot survey study of young female cancer survivors. Support Care Cancer. 2015; 23: 1663-7.
 
11) Bastings L, Baysal O, Beerendonk CC, et al. Deciding about fertility preservation after special-ist counselling. Hum Reprod. 2014; 29: 1721-9.
 
12) 小泉智恵, 安宅大輝, 拝野貴之, 他. がん・生殖医療におけるサイコソーシャルケア: 2019年までの動向. 日本がん・生殖医療学会誌. 2020; 3: 57-62.
 
13) Ehrbar V, Urech C, Rochlitz C, et al. Randomized controlled trial on the effect of an online deci-sion aid for young female cancer patients regarding fertility preservation. Hum Reprod. 2019; 34: 1726-34.
 
14) Ehrbar V, Germeyer A, Nawroth F, et al. Long-term effectiveness of an online decision aid for female cancer patients regarding fertility preservation: Knowledge, attitude, and decisional regret. Acta Obstet Gynecol Scand. 2021; 100: 1132-9.
 
15) Lawson AK, Klock SC, Pavone ME, et al. Psychological counseling of female fertility preserva-tion patients. J Psychosoc Oncol. 2015; 33: 333-53.
 
16) Gorman JR, Su HI, Pierce JP, et al. A multidimensional scale to measure the reproductive con-cerns of young adult female cancer survivors. J Cancer Surviv. 2014; 8: 218-28.
 
17) Gorman JR, Pan-Weisz TM, Drizin JH, et al. Revisiting the reproductive concerns after cancer (RCAC) scale. Psychooncology. 2019; 28: 1544-50.
 
18) Gorman JR, Drizin JH, Malcarne VL, et al. Measuring the multidimensional reproductive con-cerns of young adult male cancer survivors. J Adolesc Young Adult Oncol. 2020; 9: 613-20.
 
P.27 掲載の参考文献
1) 国立がん研究センターがん情報サービス「がん登録・統計」〔全国がん罹患モニタリング集計 (MCIJ) 〕.
 
2) 日本血液学会. 造血器腫瘍診療ガイドライン 2018年版補訂版. 東京: 金原出版; 2020.
 
3) 国立がん研究センターがん情報サービス「がん登録・統計」「がん診療連携拠点病院等院内がん登録 2017年全国集計報告書」特別集計.
 
4) Yasmin E, Mitchell R, Lane S. Preservation of fertility in teenagers and young adults treated for haematological malignancies. Lancet Haematol. 2021; 8: e149-60.
 
5) 日本癌治療学会. 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 東京: 金原出版; 2017.
 
6) 国立がん研究センター研究開発費 (30-A-13) 「がん緩和ケアのアンメットニーズに関する研究」班. AYA世代がん患者とそのご家族の支援 AYAサポートチーム活動の手引き. 2021. https://www.ncc.go.jp/jp/ncch/info/team/060/ayasupprotbook.pdf
 
P.33 掲載の参考文献
1) 国立がん研究センターがん情報サービス がん登録・統計. https://ganjoho.jp/public/life_stage/child/patients.html
 
2) がんの統計編集委員会, 編. がんの統計 '18. がん研究振興財団. 2018.
 
3) Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Com-mittee on Drugs, American Academy of Pediatrics. Pediatrics. 1995; 95: 286-94.
 
4) 文部科学省, 厚生労働省, 経済産業省. 人を対象とする生命科学・医学系研究に関する倫理指針 (令和4年3月10日一部改正, 文部科学省・厚生労働省・経済産業省告示第1号) . 2022.
 
5) Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 2500-10.
 
6) Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommenda-tions on fertility preservation in cancer patients. J Clin Oncol. 2006; 24: 2917-31.
 
7) Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005; 353: 318-21.
 
8) Signorello LB, Mulvihill JJ, Green DM, et al. Congenital anomalies in the children of cancer sur-vivors: a report from the childhood cancer survivor study. J Clin Oncol. 2012; 30: 239-45.
 
9) Signorello LB, Mulvihill JJ, Green DM, et al. Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study. Lancet. 2010; 376: 624-30.
 
10) Gunnes MW, Lie RT, Bjorge T, et al. Reproduction and marriage among male survivors of can-cer in childhood, adolescence and young adulthood: a national cohort study. Br J Cancer. 2016; 114: 348-56.
 
P.41 掲載の参考文献
1) 厚生労働省ウェブサイト. がん登録 全国がん登録 罹患数・率 報告 平成29年報告. 2020.
 
2) 国立がん研究センターがん情報サービス. 小児・AYA世代のがん罹患.
 
3) 日本乳癌学会. 乳癌診療ガイドライン(1)治療編 2022年版. 東京: 金原出版; 2022.
 
4) Moore HC, Unger JM, Phillips KA, et al; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015; 372: 923-32.
 
5) Kim I, Ryu JM, Paik HJ, et al. Fertility rates in young Korean breast cancer patients treated with gonadotropin-releasing hormone and chemotherapy. J Breast Cancer. 2017; 20: 91-7.
 
6) Leonard RCF, Adamson DJA, Bertelli G, et al; Anglo Celtic Collaborative Oncology Group and National Cancer Research Institute Trialists. GnRH agonist for protection against ovarian tox-icity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017; 28: 1811-6.
 
7) Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo) adjuvant che-motherapy for breast cancer. J Clin Oncol. 2012; 30: 533-8.
 
8) Badawy A, Elnashar A, El-Ashry M, et al. Gonadotropin-releasing hormone agonists for pre-vention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009; 91: 694-7.
 
9) Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018; 36: 1994-2001.
 
10) Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preser-vation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2020; 31: 1664-78.
 
11) Schuring AN, Fehm T, Behringer K, et al. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. part I: indications for fertility preservation. Arch Gynecol Obstet. 2018; 297: 241-55.
 
12) ESHRE Guideline Group on Female Fertility Preservation; Anderson RA, Amant F, Braat D, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020; 2020: hoaa052. 1-17.
 
13) 日本・がん生殖医療学会. 乳癌患者の妊娠・出産と生殖医療に関する診療ガイドライン 2021年版. 東京: 金原出版; 2021.
 
14) Lanbertini M, Blondeau X, Bruzzone M, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2021; 39: 3293-305.
 
15) Rosenberg E, Fredriksson A, Einbeigi Z, et al. No increased risk of relapse of breast cancer for women who give birth after assisted conception. Hum Reprod Open. 2019; 2019: hoz039.
 
16) Goldrat O, Kroman N, Peccatori FA, et al. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Eur J Cancer. 2015; 51: 1490-6.
 
17) https://bigagainstbreastcancer.org/wp-content/uploads/2023/01/sabcs-press-release.pdf
 
18) Sun Z, Niman SM, Pagani O, et al; POSITIVE Steering Committee. Estimation of historical con-trol rate for a single arm de-escalation study-Application to the POSITIVE trial. Breast. 2020; 53: 1-7.
 
P.46 掲載の参考文献
1) WHO classification of tumours editorial board. WHO Classification of Tumours of Soft Tissue and Bone. 5th ed. Lyon: IARC Press; 2020.
 
2) 日本癌治療学会. 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 東京: 金原出版; 2017.
 
3) Amin MB, Edge SB, Greene FL, et al. editors. AJCC Cancer Staging Manual, 8th ed. New York: Springer; 2017.
 
4) 日本整形外科学会骨軟部腫瘍委員会, 国立がん研究センター, 編. 平成25年度全国骨腫瘍登録一覧表. 2013.
 
5) 日本整形外科学会骨軟部腫瘍委員会, 国立がん研究センター, 編. 平成25年度全国軟部腫瘍登録一覧表. 2013.
 
6) Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23: 2004-11.
 
7) Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed che-motherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncol-ogy Group. J Clin Oncol. 2012; 30: 4148-54.
 
8) Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized con-trolled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008; 113: 573-81.
 
9) Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommenda-tions on fertility preservation in cancer patients. J Clin Oncol. 2006; 24: 2917-31.
 
10) Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with can-cer. J Clin Oncol. 2010; 28: 4831-41.
 
11) Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 2500-10.
 
P.51 掲載の参考文献
1) Sehring J, Hussain A, Grimm L, et al. A call to action: unified clinical practice guidelines for oncofertility care. J Assist Reprod Genet. 2021; 38: 1745-54.
 
2) Noone AM, Howlader N, Krapcho M, et al. editors. SEER Cancer Statistics Review, 1975-2015. Bethesda: National Cancer Institute. 2018. https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER website, April 2018.
 
3) Lee SJ, Schover LR, Partridge AH, et al; American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006; 24: 2917-31.
 
4) Loren AW, Mangu PB, Beck LN, et al; American Society of Clinical Oncology. Fertility preser-vation for patients with cancer: American Society of Clinical Oncology clinical practice guide-line update. J Clin Oncol. 2013; 31: 2500-10.
 
5) Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018; 36: 1994-2001.
 
6) https://www.asco.org/research-guidelines/quality-guidelines/guidelines/patient-and-survivor-care#/9661
 
7) Anazodo A, Laws P, Logan S, et al. How can we improve oncofertility care for patients? A sys-tematic scoping review of current international practice and models of care. Hum Reprod Update. 2019; 25: 159-79.
 
8) Sehring J, Hussain A, Grimm L, et al. A call to action: unified clinical practice guidelines for oncofertility care. J Assist Reprod Genet. 2021; 38: 1745-54.
 
P.61 掲載の参考文献
1) Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommenda-tions on fertility preservation in cancer patients. J Clin Oncol. 2006; 24: 2917-31.
 
2) von Wolff M, Montag M, Dittrich R, et al. Fertility preservation in women--a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011; 284: 427-35.
 
3) Backhus LE, Kondapalli LA, Chang RJ, et al. Oncofertility consortium consensus statement: guidelines for ovarian tissue cryopreservation. Cancer Treat Res. 2007; 138: 235-9.
 
4) Pentheroudakis G, Pavlidis N, Castiglione M. Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008; 19 Suppl 2: ii108-9.
 
5) Pentheroudakis G, Orecchia R, Hoekstra HJ, et al. Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5: v266-73.
 
6) Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†. Ann Oncol. 2020; 31: 1664-78.
 
7) Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001; 7: 363-9.
 
8) Kenney LB, Antal Z, Ginsberg JP, et al. Improving male reproductive health after childhood, adolescent, and young adult cancer: progress and future directions for survivorship research. J Clin Oncol. 2018; 36: 2160-8.
 
9) Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with prema-ture ovarian insufficiency. Hum Reprod. 2016; 31: 926-37.
 
10) Jacobson MH, Mertens AC, Spencer JB, et al. Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all. Fertil Steril. 2016; 105: 765-72. e4.
 
11) Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hor-mone in women. Hum Reprod Update. 2014; 20: 370-85.
 
12) Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019; 25: 673-93.
 
13) Adriaens I, Smitz J, Jacquet P. The current knowledge on radiosensitivity of ovarian follicle development stages. Hum Reprod Update. 2009; 15: 359-77.
 
14) Brannstrom M, Dahm-Kahler P. Uterus transplantation and fertility preservation. Best Pract Res Clin Obstet Gynaecol. 2019; 55: 109-16.
 
15) Rienzi L, Gracia C, Maggiulli R, et al. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017; 23: 139-55.
 
16) von Wolff M, Capp E, Jauckus J, et al. Timing of ovarian stimulation in patients prior to gonad-otoxic therapy: an analysis of 684 stimulations. Eur J Obstet Gynecol Reprod Biol. 2016; 199: 146-9.
 
17) Tsampras N, Gould D, Fitzgerald CT. Double ovarian stimulation (DuoStim) protocol for fertil-ity preservation in female oncology patients. Hum Fertil (Camb) . 2017; 20: 248-53.
 
18) Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimula-tion for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017; 32: 1033-45.
 
19) Moravek MB, Confino R, Smith KN, et al. Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertil Steril. 2018; 109: 349-55.
 
20) Oktay K, Turan V, Bedoschi G, et al. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015; 33: 2424-9.
 
21) Gellert SE, Pors SE, Kristensen SG, et al. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018; 35: 561-70.
 
22) Diaz-Garcia C, Domingo J, Garcia-Velasco JA, et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril. 2018; 109: 478-85. e2.
 
23) Wallace WH, Smith AG, Kelsey TW, et al. Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol. 2014; 15: 1129-36.
 
24) Irtan S, Orbach D, Helfre S, et al. Ovarian transposition in prepubescent and adolescent girls with cancer. Lancet Oncol. 2013; 14: e601-8.
 
25) Steigrad S, Hacker NF, Kolb B. In vitro fertilization surrogate pregnancy in a patient who under-went radical hysterectomy followed by ovarian transposition, lower abdominal wall radiother-apy, and chemotherapy. Fertil Steril. 2005; 83: 1547-9.
 
26) Gubbala K, Laios A, Gallos I, et al. Outcomes of ovarian transposition in gynaecological can-cers; a systematic review and meta-analysis. J Ovarian Res. 2014; 7: 69.
 
27) Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys. 1990; 19: 873-80.
 
28) Roness H, Kashi O, Meirow D. Prevention of chemotherapy-induced ovarian damage. Fertil Steril. 2016; 105: 20-9.
 
29) Anderson RA, Amant F, Braat D, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020; 2020: hoaa052.
 
30) Group EFFPGD. Female Fertility Preservation Guideline of the European Society of Human Reproduction and Embryology 2020. Available from: https://www.eshre.eu/FFPguideline.
 
31) Peate M, Meiser B, Hickey M, et al. The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. Breast Cancer Res Treat. 2009; 116: 215-23.
 
32) Goossens J, Delbaere I, Van Lancker A, et al. Cancer patients' and professional caregivers' needs, preferences and factors associated with receiving and providing fertility-related infor-mation: a mixed-methods systematic review. Int J Nurs Stud. 2014; 51: 300-19.
 
33) Silva C, Almeida-Santos AT, Melo C, et al. Antineoplastic agents and (in) fertility: informing patients to improve decisions. J Adolesc Young Adult Oncol. 2018; 7: 306-14.
 
34) Tauchmanova L, Selleri C, De Rosa G, et al. Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. Hum Reprod. 2003; 18: 1410-6.
 
35) Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011; 96: 1336-43.
 
36) van der Kaaij MA, Heutte N, Meijnders P, et al. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treat-ment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol. 2012; 30: 291-9.
 
37) Akhtar S, Youssef I, Soudy H, et al. Prevalence of menstrual cycles and outcome of 50 preg-nancies after high-dose chemotherapy and auto-SCT in non-Hodgkin and Hodgkin lymphoma patients younger than 40 years. Bone Marrow Transplant. 2015; 50: 1551-6.
 
38) Silva C, Caramelo O, Almeida-Santos T, et al. Factors associated with ovarian function recov-ery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod. 2016; 31: 2737-49.
 
39) Freour T, Barriere P, Masson D. Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Eur J Cancer (Oxford, England: 1990) . 2017; 74: 1-8.
 
40) Lambertini M, Ceppi M, Cognetti F, et al. Dose-dense adjuvant chemotherapy in premeno-pausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies. Eur J Cancer (Oxford, England: 1990) . 2017; 71: 34-42.
 
41) Dezellus A, Barriere P, Campone M, et al. Prospective evaluation of serum anti-Mullerian hor-mone dynamics in 250 women of reproductive age treated with chemotherapy for breast can-cer. Eur J Cancer (Oxford, England: 1990). 2017; 79: 72-80.
 
42) Anderson C, Engel SM, Weaver MA, et al. Birth rates after radioactive iodine treatment for dif-ferentiated thyroid cancer. Int J Cancer. 2017; 141: 2291-5.
 
43) Anderson RA, Rosendahl M, Kelsey TW, et al. Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer (Oxford, England: 1990) . 2013; 49: 3404-11.
 
44) Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013; 99: 477-83.
 
45) Peigne M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemo-therapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol. 2014; 12: 26.
 
46) Su HC, Haunschild C, Chung K, et al. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer. 2014; 120: 3691-8.
 
47) Hamy AS, Porcher R, Eskenazi S, et al. Anti-Mullerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies. Reprod Biomed Online. 2016; 32: 299-307.
 
48) Rienzi L, Cobo A, Paffoni A, et al. Consistent and predictable delivery rates after oocyte vitrifi-cation: an observational longitudinal cohort multicentric study. Hum Reprod. 2012; 27: 1606-12.
 
49) Cobo A, Garcia-Velasco JA, Domingo J, et al. Is vitrification of oocytes useful for fertility pres-ervation for age-related fertility decline and in cancer patients? Fertil Steril. 2013; 99: 1485-95.
 
50) Druckenmiller S, Goldman KN, Labella PA, et al. Successful oocyte cryopreservation in repro-ductive-aged cancer survivors. Obstet Gynecol. 2016; 127: 474-80.
 
51) Massarotti C, Scaruffi P, Lambertini M, et al. State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. Cancer Treat Rev. 2017; 57: 50-7.
 
52) Cobo A, Garcia-Velasco J, Domingo J, et al. Elective and onco-fertility preservation: factors related to IVF outcomes. Hum Reprod. 2018; 33: 2222-31.
 
53) Rodriguez-Wallberg KA, Waterstone M, Anastacio A. Ice age: cryopreservation in assisted reproduction-an update. Reprod Biol. 2019; 19: 119-26.
 
54) Dolmans MM, Demylle D, Martinez-Madrid B, et al. Efficacy of in vitro fertilization after chemo-therapy. Fertil Steril. 2005; 83: 897-901.
 
55) Barcroft J, Dayoub N, Thong KJ. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation. J Assist Reprod Genet. 2013; 30: 1407-13.
 
56) Courbiere B, Decanter C, Bringer-Deutsch S, et al. Emergency IVF for embryo freezing to pre-serve female fertility: a French multicentre cohort study. Hum Reprod. 2013; 28: 2381-8.
 
57) Debrock S, Peeraer K, Fernandez Gallardo E, et al. Vitrification of cleavage stage day 3 embryos results in higher live birth rates than conventional slow freezing: a RCT. Hum Reprod. 2015; 30: 1820-30.
 
58) Dolmans MM, Hollanders de Ouderaen S, Demylle D, et al. Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment. J Assist Reprod Genet. 2015; 32: 1233-7.
 
59) Alvarez RM, Ramanathan P. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response. Hum Reprod. 2018; 33: 2051-9.
 
60) Rodriguez-Wallberg KA, Marklund A, Lundberg F, et al. A prospective study of women and girls undergoing fertility preservation due to oncologic and non-oncologic indications in Sweden-Trends in patients' choices and benefit of the chosen methods after long-term follow up. Acta Obsted Gynecol Scand. 2019; 98: 604-15.
 
61) Ovarian Stimulation T, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI(†). Hum Reprod Open. 2020; 2020: hoaa009.
 
62) Pacheco F, Oktay K. Current success and efficiency of autologous ovarian transplantation: a meta-analysis. Reprod Sci (Thousand Oaks, Calif) . 2017; 24: 1111-20.
 
63) Paradisi R, Macciocca M, Vicenti R, et al. New insights in the selection and management of can-cer patients applicants for ovarian tissue cryopreservation. Gynecol Endocrinol. 2016; 32: 881-5.
 
64) Fabbri R, Vicenti R, Macciocca M, et al. Morphological, ultrastructural and functional imaging of frozen/thawed and vitrified/warmed human ovarian tissue retrieved from oncological patients. Hum Reprod. 2016; 31: 1838-49.
 
65) Dalman A, Deheshkar Gooneh Farahani NS, Totonchi M, et al. Slow freezing versus vitrification technique for human ovarian tissue cryopreservation: An evaluation of histological changes, WNT signaling pathway and apoptotic genes expression. Cryobiology. 2017; 79: 29-36.
 
66) Shi Q, Xie Y, Wang Y, et al. Vitrification versus slow freezing for human ovarian tissue cryopres-ervation: a systematic review and meta-anlaysis. Sci Rep. 2017; 7: 8538.
 
67) Beckmann MW, Dittrich R, Lotz L, et al. Operative techniques and complications of extraction and transplantation of ovarian tissue: the Erlangen experience. Arch Gynecol Obstet. 2017; 295: 1033-9.
 
68) Lambertini M, Goldrat O, Ferreira AR, et al. Reproductive potential and performance of fertil-ity preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018; 29: 237-43.
 
69) Lambertini M, Di Maio M, Poggio F, et al. Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. Reprod Biomed Online. 2019; 38: 835-44.
 
70) Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releas-ing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015; 26: 2408-19.
 
71) Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a Systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018; 36: 1981-90.
 
72) Gilani MM, Hasanzadeh M, Ghaemmaghami F, et al. Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy. Asia-Pac J Clin Oncol. 2007; 3: 79-83.
 
73) Senra JC, Roque M, Talim MCT, et al. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018; 51: 77-86.
 
74) Hoekman EJ, Broeders E, Louwe LA, et al. Ovarian function after ovarian transposition and additional pelvic radiotherapy: a systematic review. Eur J Surg Oncol. 2019; 45: 1328-40.
 
75) Hartnett KP, Mertens AC, Kramer MR, et al. Pregnancy after cancer: does timing of concep-tion affect infant health? Cancer. 2018; 124: 4401-7.
 
76) Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. Breast Cancer Res Treat. 2016; 160: 347-60.
 
77) Sun C, Ding X, Wu Y, et al. Meta-analysis of associations between maternal breast cancer and the risk of adverse delivery outcomes. Int J Gynaecol Obstet. 2018; 140: 146-52.
 
78) Lee HM, Kim BW, Park S, et al. Childbirth in young Korean women with previously treated breast cancer: The SMARTSHIP study. Breast Cancer Res Treat. 2019; 176: 419-27.
 
79) Schuurman TN, Witteveen PO, van der Wall E, et al. Tamoxifen and pregnancy: an absolute contraindication? Breast Cancer Res Treat. 2019; 175: 17-25.
 
80) Lambertini M, Martel S, Campbell C, et al. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast can-cer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer. 2019; 125: 307-16.
 
81) Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996; 87: 3045-52.
 
82) Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr. 2005; 64-8.
 
83) Signorello LB, Mulvihill JJ, Green DM, et al. Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study. Lancet. 2010; 376: 624-30.
 
84) Teh WT, Stern C, Chander S, et al. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int. 2014; 2014: 482968.
 
85) van de Loo L, van den Berg MH, Overbeek A, et al. Uterine function, pregnancy complications,and pregnancy outcomes among female childhood cancer survivors. Fertil Steril. 2019; 111: 372-80.
 
P.70 掲載の参考文献
1) 日本癌治療学会, 編. 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 東京: 金原出版; 2017.
 
2) ASCO Recommendations on Fertility Preservation in Cancer Patients. J Clin Oncol. 2006; 24: 2917-31.
 
3) Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 2500-10.
 
4) von Wolff M, Montag M, Dittrich R, et al. Fertility preservation in women--a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphomaand borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011; 284: 427-35.
 
5) ISFP Practice Committee, Kim SS, Donnez J, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012; 29: 465-8.
 
6) Schmidt KT, Andersen CY; ISFP Practice Committee. Recommendations for fertility preserva-tion in patients with lymphomas. J Assist Reprod Genet. 2012; 29: 473-7.
 
7) Klemp JR, Kim SS; ISFP Practice Committee. Fertility preservation in young women with breast cancer. J Assist Reprod Genet. 2012; 29: 469-72.
 
8) Sanada Y, Harada M, Kunitomi C, et al. A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients. J Obstet Gynaecol Res. 2019; 45: 2021-8.
 
9) 日本医療研究開発機構 (AMED) 革新的がん医療実用化研究事業 生殖機能温存がん治療法の革新的発展にむけた総合的プラットフォームの形成研究班 (代表: 大須賀穣) , 編. がん患者の妊孕性温存のための診療マニュアル. 東京: 金原出版; 2019.
 
10) Kunitomi C, Harada M, Sanada Y, et al. The possible effects of the Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 on the practice of fertility preservation in female cancer patients in Japan. Reprod Med Biol. 2022; 21: e12453.
 
P.72 掲載の参考文献
1) Mitchell AJ, Ferguson DW, Gill J, et al. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013; 14: 721-32.
 
2) Canada AL, Schover LR. The psychosocial impact of interrupted childbearing in long-term female cancer survivors. Psychooncology. 2012; 21: 134-43.
 
3) 小泉智恵. Q43 短期間のうちに多くの意思決定を迫られる患者にどう関わる?-臨床心理士の立場から. In: 大須賀譲, 他. がん・生殖医療ハンドブック. 大阪: メディカ出版; 2017. p. 298-302.
 
4) 奈良和子. 妊孕性温存が困難な場合の心理支援～女性～. In: 鈴木 直, 他編. ヘルスケアプロバイダーのためのがん・生殖医療. 大阪: メディカ出版; 2019. p. 156-9.
 
5) 杉本公平. 親になる支援 家族づくりの在り方. In: 鈴木 直,他編. ヘルスケアプロバイダーのためのがん・生殖医療. 大阪: メディカ出版; 2019. p. 164-7.
 
P.74 掲載の参考文献
1) 奈良和子. 4 妊孕性温存とチーム医療 D 心理士の役割. In: 柴原浩章, 編. Fertility Preservation～妊孕性温存のすべて～. 東京: 中外医学社; 2021. p. 212-7.
 
2) 山口 隆, 東梅久子, 矢野美穂子, 他. 悪性疾患に対する静止凍結保存の検討. 日受精着床会誌. 2015; 32: 67-71.
 
3) 平成 27-29 年度厚生労働科学研究費補助金 (がん対策推進総合研究事業) 「総合的な思春期・若年成人 (AYA) 世代のがん対策の在り方に関する研究」班. 医療従事者が知っておきたいAYA世代がんサポートガイド. p. 16.
 
4) ポーリン・ボス, 南山浩二, 訳. 「さよなら」のない別れ 別れのない「さよなら」: あいまいな喪失. 東京: 東京学文社; 2005. p. 181.
 
5) Doka JK. Disenfranchise grief recognizing hidden sorrow. New York: Lexington Books; 1989. p. 347.
 
P.76 掲載の参考文献
1) Freeman HP, Muth BJ, Kerner JF. Expanding access to cancer screening and clinical follow-up among the medically underserved. Cancer Pract. 1995; 3: 19-30.
 
2) Bernardo BM, Zhang X, Beverly Hery CM, et al. The efficacy and cost-effectiveness of patient navigation programs across the cancer continuum: a systematic review. Cancer. 2019; 125: 2747-61.
 
3) Basu M, Linebarger J, Gabram SG, et al. The effect of nurse navigation on timeliness of breast cancer care at an academic comprehensive cancer center. Cancer. 2013; 119: 2524-31.
 
4) 渡邊知映. がん患者に対する治療開始前妊孕性対策における看護師によるサポート体制の実態と課題の検討. 平成28年度厚生労働省子ども・子育て支援推進調査研究事業研究事業総括報告書 (研究事業総括 鈴木 直) . 2016.
 
P.80 掲載の参考文献
1) 赤阪未来, 前沢忠志, 西岡美喜子, 他. 三重県下のがん診療連携病院における若年がん患者の妊孕性温存に関する医師, 薬剤師, 看護師を対象とした意識調査. 日病薬師会誌. 2021; 57: 1379-85.
 
2) Boyajian RN, Grose A, Grenon N, et al. Desired elements and timing of cancer survivorship care: one approach may not fit all. J Oncol Pract. 2014; 10: e293-8.
 
3) 日本癌治療学会, 編. 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 東京: 金原出版; 2017.
 
4) Briggs GG, Freeman RK, Towers CV, et al. Drugs in Pregnancy and Lactation. 11th ed. Amster-dam: Wolters Kluwer Health; 2017.
 
5) U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) . Oncology Pharmaceuticals: Reproductive toxicitytesting and labeling recommendations guidance for industry. 2019 https://www.fda.gov/media/124829/download
 
P.84 掲載の参考文献
1) 泊 博幸, 鈴木 直. 本邦における胚培養士を対象とした妊孕性温存療法の実施状況調査. 厚生労働科学研究成果データベース. 2022. p. 119-28.
 
2) Schiewe MC, Freeman M, Whitney JB, et al. Comprehensive assessment of cryogenic storage risk and quality management concerns: best practice guidelines for ART labs. J Assist Reprod. 2019; 36: 5-14.
 
3) Yamada M, Ishikawa T, Iwasa T, et al. Guidelines for reproductive medicine in Japan. Reprod Med Biol. 2022; 21: e12483. https://doi.org/10.1002/rmb2.12483.
 
P.86 掲載の参考文献
1) De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country andage: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014; 15: 23-34.
 
2) Smith MA, Altekruse SF, Adamson PC, et al. Declining childhood and adolescent cancer mor-tality. Cancer. 2014; 120: 2497-506.
 
3) Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: life-long risks andresponsibilities. Nat Rev Cancer. 2014; 14: 61-70.
 
4) Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017; 377: 1657-65.
 
5) Harada T, Kuji N, Ishihara O, et al. Guideline for cryopreservation of unfertilized eggs and ovar-ian tissues in Japan Society of Reproductive Medicine: Ethics Committee in Japan Society of Reproductive Medicine. Reprod Med Biol. 2019; 18: 3-6.
 
6) Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. FertilSteril. 2019; 112: 1022-33.
 

Chapter II 妊孕性温存療法

P.91 掲載の参考文献
1) von Wolff M, Montag M, Dittrich R, et al. Fertility preservation in women-a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphomaand borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011; 284: 427-35.
 
2) Sopa N, Larsen EC, Hvidman HW, et al. An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI. Eur J Obstet Gynecol Reprod Biol. 2019; 237: 42-7.
 
3) Cimadomo D, Vaiarelli A, Colamaria S, et al. Luteal phase anovulatory follicles result in the pro-duction of competent oocytes: intra-patient paired case-control study comparing follicularversus luteal phase stimulations in the same ovarian cycle. Hum Reprod. 2018; 33: 1442-8.
 
4) Sunderam S, Boulet SL, Kawwass JF, et al. Comparing fertilization rates from intracytoplasmic sperm injection to conventional in vitro fertilization among women of advanced age with non-male factor infertility: a meta-analysis. Fertil Steril. 2020; 113: 354-63. e1.
 
5) Glujovsky D, Blake D, Bardach A, et al. Cleavage stage versus blastocyst stage embryo trans-fer in assisted reproductive technology. Cochrane Database Syst Rev. 2012; (7) : CD002118.
 
P.98 掲載の参考文献
1) Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013; 99: 37-43.
 
2) Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 2500-10.
 
3) 日本産科婦人科学会. 医学的適応による未受精卵子, 胚 (受精卵) および卵巣組織の凍結・保存に関する見解. 日産婦会誌. 2019; 71: 609-11.
 
4) Rienzi L, Gracia C, Maggiulli R, et al. Oocyte, embryo and blastocyst cryopreservation in ART:systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017; 23: 139-55.
 
5) Mori C, Yabuuchi A, Ezoe K, et al. Hydroxypropyl cellulose as an option for supplementation of cryoprotectant solutions for embryo vitrification in human assisted reproductive technologies. Reprod Biomed Online. 2015; 30: 613-21.
 
6) Kato K, Ochi M, Nakamura Y, et al. A multi-centre, retrospective case series of oocyte cryo-preservation in unmarried women diagnosed with haematological malignancies. Hum Reprod Open. 2021; 2021: hoaa064.
 
P.103 掲載の参考文献
1) Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesi during the human men-strual cycle: a review. Hum Reprod Update. 2012; 18: 73-91.
 
2) Sanada Y, Harada M, Kunitomi C, et al. A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients. J Obstet Gynaecol Res. 2019; 45: 2021-8.
 
3) Anderson RA, Kinniburgh D, Baird DT. Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treat-ment. Hum Reprod. 1999; 14: 2665-8.
 
4) Humaidan P, Bungum L, Bungum M, et al. Reproductive outcome using a GnRH antagonist (cet-rorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod Biomed Online. 2005; 11: 679-84.
 
5) von Wolff M, Thaler CJ, Frambach T, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009; 92: 1360-5.
 
6) Cakmak H, Katz A, Cedars MI, et al. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013; 100: 1673-80.
 
7) Von Wolff M, Capp E, Jauckus J, et al. Timing of ovarian stimulation in patients prior to gonad-otoxic therapy: an analysis of 684 stimulations. Eur J Obstet Gynecol Reprod Biol. 2016; 199: 146-9.
 
8) Boots CE, Meister M, Cooper AR, et al. Ovarian stimulation in the luteal phase: systematic review and meta-analysis. J Assist Reprod Genet. 2016; 33: 971-80.
 
9) Pereira N, Voskuilen-Gonzalez A, Hancock K, et al. Random-start ovarian stimulation in women desiring elective cryopreservation of oocytes. Reprod Biomed Online. 2017; 35: 400-6.
 
10) Nakasuji T, Kawai K, Ishikawa T, et al. Random-start ovarian stimulation with aromatase inhib-itor for fertility preservation in women with Japanese breast cancer. Reprod Med Biol. 2019; 18: 167-72.
 
11) Kuang Y, Hong Q, Chen Q, et al. Luteal-phase ovarian stimulation is feasible for producing com-petent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014; 101: 105-11.
 
12) Chen H, Wang Y, Lyu Q, et al. Comparison of live-birth defects after luteal-phase ovarian stim-ulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo trans-fer cycles. Fertil Steril. 2015; 103: 1194-201.
 
13) Wald K, Cakmak H, Mok-Lin E, et al. Back-to-back random-start ovarian stimulation prior to chemotherapy to maximize oocyte yield. J Assist Reprod Genet. 2019; 36: 1161-8.
 
P.110 掲載の参考文献
1) Franik S, Eltrop SM, Kremer JA, et al. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018; 5 (5) : CD010287.
 
2) de Medeiros SF, Rodgers RJ, Norman RJ. Adipocyte and steroidogenic cell cross-talk in poly-cystic ovary syndrome. Hum Reprod Update. 2021; 27: 771-96.
 
3) Ghosh D, Lo J, Egbuta C. Recent progress in the discovery of next generation inhibitors of aro-matase from the structure-function perspective. J Med Chem. 2016; 59: 5131-48.
 
4) Rose BI, Brown SE. A review of the physiology behind letrozole applications in infertility: are current protocols optimal? J Assist Reprod Genet. 2020; 37: 2093-104.
 
5) Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. HumReprod. 2018; 33: 1602-18.
 
6) Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns con-ceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril. 2006; 85:1761-5.
 
7) Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a pro-spective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005; 23: 4347-53.
 
8) Sonmezer M, Turkcuoglu I, Coskun U, et al. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011; 95: 2125 e9-11.
 
9) Shapira M, Raanani H, Meirow D. IVF for fertility preservation in breast cancer patients--effi-cacy and safety issues. J Assist Reprod Genet. 2015; 32: 1171-8.
 
10) Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimula-tion for fertility preservation in women with early breast cancer: a systematic review. HumReprod. 2017; 32: 1033-45.
 
11) Bonardi B, Massarotti C, Bruzzone M, et al. Efficacy and safety of controlled ovarian stimula-tion with or without letrozole co-administration for fertility preservation: a systematic review and meta-analysis. Front Oncol. 2020; 10: 574669.
 
12) Taylan E, Oktay KH. Current state and controversies in fertility preservation in women with breast cancer. World J Clin Oncol. 2017; 8: 241-8.
 
13) Tatsumi T, Jwa SC, Kuwahara A, et al. No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology. Hum Reprod. 2017; 32: 125-32.
 
14) Pundir J, Achilli C, Bhide P, et al. Risk of foetal harm with letrozole use in fertility treatment: a systematic review and meta-analysis. Hum Reprod Update. 2021; 27: 474-85.
 
15) Oktay K, Turan V, Bedoschi G, et al. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015; 33: 2424-9.
 
P.114 掲載の参考文献
1) Cakmak H, Rosen MP. Random-start ovarian stimulation in patients with cancer. Curr Opin Obstet Gynecol. 2015; 27: 215-21.
 
2) Kuang Y, Chen Q, Hong Q, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol) . Reprod Biomed Online. 2014; 29: 684-91.
 
3) Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human men-strual cycle: a review. Hum Reprod Update. 2012; 18: 73-91.
 
4) 浮田祐司, 浮田美里, 柴原浩章. ART 卵巣刺激における日程調整法. 臨婦産. 2019; 73: 687-92.
 
5) Vaiarelli A, Cimadomo D, Trabucco E, et al. Double stimulation in the same ovarian cycle (DuoS-tim) to maximize the number of oocytes retrieved from poor prognosis patients: a multicenter experience and SWOT Analysis. Front Endocrinol (Lausanne) . 2018; 9: 317.
 
6) Ubaldi FM, Capalbo A, Vaiarelli A, et al. Follicular versus luteal phase ovarian stimulation duringthe same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a sim-ilar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016; 105: 1488-95 e1.
 
7) Cimadomo D, Vaiarelli A, Colamaria S, et al. Luteal phase anovulatory follicles result in the pro-duction of competent oocytes: intra-patient paired case-control study comparing follicular versus luteal phase stimulations in the same ovarian cycle. Hum Reprod. 2018; 33: 1442-8.
 
8) Stimulation EGGoO, Bosch E, Broer S, et al. Erratum: ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open. 2020; 2020: hoaa067.
 
P.119 掲載の参考文献
1) Practice Committees of the American Society for Reproductive Medicine, the Society of Repro-ductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. Invitro maturation: a committee opinion. Fertil Steril. 2021; 115: 298-304.
 
2) Cha KY, Koo JJ, Ko JK, et al. Pregnancy after in vitro fertilization of human oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril. 1991; 55: 109-13.
 
3) Trounson A, Wood C, Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from unstimulated polycystic patients. Fertil Steril. 1994; 62: 353-62.
 
4) 福田愛作, 河田 淳, 當仲正丈, 他. 非刺激周期婦人よりの未成熟卵体外受精の試み. 日受精着床会誌. 2001; 18: 1-4.
 
5) 福田愛作, 森本義晴. 未熟卵体外成熟顕微授精胚の凍結融解胚移植による妊娠. 産科と婦人科. 2001; 12: 1871-6.
 
6) Nugeira D, Staessen C, Van de Velde H, et al. Nuclear status and cytogenetics of embryos derived from in vitro matured oocytes. Fertil Steril. 2000; 74: 295-8.
 
7) Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. Fertil Steril. 2013; 99: 663-6.
 
8) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018; 110: 364-79.
 
9) Grynberg M, Poulain M, le Parco S, et al. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation inbreast cancer patients. Hum Reprod. 2016; 31: 623-9.
 
10) Karavani G, Schachter-Safrai N, Revel A, et al. In vitro maturation rates in young premenarche patients. Fertil Steril, 2019; 112: 315-22.
 
11) Creux H, Monnier P, Son W-Y, et al. Thirteen years' experience in fertility preservation for can-cer patients after in vitro fertilization and in vitro maturation treatments. J Assist Reprod Genet. 2018; 35: 583-92.
 
P.127 掲載の参考文献
1) 日本産科婦人科学会. 医学的適応による未受精卵子, 胚 (受精卵) および卵巣組織の採取, 凍結保存に関する見解 (2019年改定) . 2019. http://www.jsog.or.jp/modules/statement/index.php?content_id=23
 
2) Rauff S, Giorgione V, Andersen CY. Potential malignant cell contamination in transplanted ovarian tissue. Expert Opin Biol Ther. 2016: 16: 285-9.
 
3) Dolmans MM, Luyckx V, Donnez J, et al. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril. 2013; 99: 1514-22.
 
4) Chung K, Donnez J, Ginsburg E, et al. Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril. 2013; 99: 1534-42.
 
5) Roness H, Meirow D. Fertility Preservation: follicle reserve loss in ovarian tissue transplanta-tion. Reproduction. 2019; 158: F35-44.
 
6) Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopre-served ovarian tissue. Lancet. 2004; 364: 1405-10.
 
7) Donnez J, Dolmans MM, Andersen CY, et al. Restration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril. 2013; 99: 1503-13.
 
8) Donnez J, Silber S, Andersen CY, et al. Children born after autotransplantation of cryopre-served ovarian tissue. A review of 13 live births. An Med. 2011; 43: 437-50.
 
9) Dolmans MM, Donez J, Camboni A, et al. IVF outcomes in patients with orthotopically trans-planted ovarian tissue. Hum Reprod. 2009; 24: 2778-87.
 
10) Amorim C, David A, Langendonckt A, et al. Vitrification of human ovarian tissue: effect of dif-ferent solutions and procedures. Fertil Steril. 2011; 95: 1094-7.
 
11) Shi Q, Xie Y, Wang Y, et al. Vitrification versus slow freezing for human ovarian tissue cryo-preservarion: asystematic review and meta-analysis. Sci Rep. 2017; 7: 8538.
 
12) Beckmann MW, Lotz L, Toth B, et al. Concept paper on the technique of cryopreservation,removal and transplantation of ovarian tissue for fertility preservation. Geburtshilfe Frauen-heilkd. 2019: 79: 53-62.
 
13) Schonenfeldt VV, Chandolia R, Sonntag B, et al. FSH prevents depletion of the resting follicle pool by promoting follicular number and morphology in fresh and cryopreserved primateovarian tissues following xenografting. Reprod Biol Endocrinol. 2012; 10: 98.
 
14) Von Wolff M, Germeyer A, Liebenthron J, et al. Practical recommendations for fertility preser-vation in women by the FertiPROTEKT network. Part II: fertility preservation techniques. Arch Gynecol Obstet. 2018; 297: 257-67.
 
15) McLaughlin M, Albertini DF, Wallace WH, et al. Metaphase II oocytes from human unilaminar follicles grown in a multi-step culture system. Hum Reprod. 2018; 24: 135-42.
 
16) Chiti MC, Dolmans MM, Lucci CM, et al. Further insights into the impact of mouse follicle stageon graft outcome in an artificial ovary environment, Hum Reprod. 2017; 23: 381-92.
 
17) Morohaku K, Tanimoto R, Sasaki K, et al. Complete in vitro generation of fertile oocytes from mouse primordial germ cells. Proc Natl Acad Sci U S A. 2016; 113: 9021-6.
 
18) Gellert SE, Pors SE, Kristensen SG, et al. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018; 35: 561-70.
 
19) Van der Ven H, Liebenthron J, Beckmann M, et al. FertiPROTEKT network. Ninety-five orthot-opic transplantation in 74 women of ovarian tissue after cytotoxic trearment in a fertility pres-ervation network: tissue activity, pregnancy and delivery rates. Hum Reprod. 2016; 31: 2031-41.
 
20) Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017; 377: 1657-65.
 
P.135 掲載の参考文献
1) Morarji K, McArdle O, Hui K, et al. Ovarian function after chemotherapy in young breast can-cer survivors. Curr Oncol. 2017; 24: 494-502.
 
2) Meirow D, Biederman H, Anderson RA, et al. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010; 53: 727-39.
 
3) Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treat-ment for Hodgkin's disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys. 1990; 19: 873-80.
 
4) Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular dam-age with an analogue of gonadotropin-releasing hormone. Lancet. 1981; 1: 1132-4.
 
5) Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018; 36: 1994-2001.
 
6) Lee JH, Choi YS. The role of gonadotropin-releasing hormone agonists in female fertility pres-ervation. Clin Exp Reprod Med. 2021; 48: 11-26.
 
7) Kalich-Philosoph L, Roness H, Carmely A, et al. Cyclophosphamide triggers follicle activation and "burnout" ; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013; 5: 185ra62.
 
8) Blumenfeld Z, Evron A. Endocrine prevention of chemotherapy-induced ovarian failure. Curr Opin Obstet Gynecol. 2016; 28: 223-9.
 
9) Morgan S, Anderson RA, Gourley C, et al. How do chemotherapeutic agents damage theovary? Hum Reprod Update. 2012; 18: 525-35.
 
10) Meirow D, Dor J, Kaufman B, et al. Cortical fibrosis and blood-vessels damage in human ova-ries exposed to chemotherapy: potential mechanisms of ovarian injury. Hum Reprod. 2007; 22: 1626-33.
 
11) Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007; 110: 2222-9.
 
12) Abir R, Ben-Haroush A, Felz C, et al. Selection of patients before and after anticancer treat-ment for ovarian cryopreservation. Hum Reprod. 2008; 23: 869-77.
 
13) Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood. 1981; 58: 849-51.
 
14) Poggio F, Lambertini M, Bighin C, et al. Potential mechanisms of ovarian protection with gonad-otropin-releasing hormone agonist in breast cancer patients: a review. Clin Med Insights Reprod Health. 2019; 13: 1179558119864584.
 
15) Patel H, Bhartiya D, Parte S, et al. Follicle stimulating hormone modulates ovarian stem cells through alternately spliced receptor variant FSH-R3. J Ovarian Res. 2013; 6: 52.
 
16) Oktay K, Briggs D, Gosden RG. Ontogeny of follicle-stimulating hormone receptor gene expres-sion in isolated human ovarian follicles. J Clin Endocrinol Metab. 1997; 82: 3748-51.
 
17) Kitajima Y, Endo T, Nagasawa K, et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology. 2006; 147: 694-9.
 
18) Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study oneffects of raloxifene and hormone replacement therapy on plasma no concentrations, endo-thelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterio-scler Thromb Vasc Biol. 2001; 21: 1512-9.
 
19) Grundker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol. 2003; 1: 65.
 
20) Imai A, Sugiyama M, Furui T, et al. Direct protection by a gonadotropin-releasing hormone ana-log from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest. 2007; 63: 102-6.
 
21) Morita Y, Perez GI, Paris F, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med. 2000; 6: 1109-14.
 
22) Li F, Turan V, Lierman S, et al. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Hum Reprod. 2014; 29: 107-13.
 
23) Zelinski MB, Murphy MK, Lawson MS, et al. In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates. Fertil Steril. 2011; 95: 1440-5.
 
24) Johnson J, Canning J, Kaneko T, et al. Germline stem cells and follicular renewal in the postna-tal mammalian ovary. Nature. 2004; 428: 145-50.
 
25) Scaruffi P, Stigliani S, Cardinali B, et al. Gonadotropin releasing hormone agonists have ananti-apoptotic effect on cumulus cells. Int J Mol Sci. 2019; 20: 6045.
 
26) Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG37 ZORO study. J Clin Oncol. 2011; 29: 2334-41.
 
27) Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo) adjuvant che-motherapy for breast cancer. J Clin Oncol. 2012; 30: 533-8.
 
28) Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemo-therapyinduced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013; 121:78-86.
 
29) Lambertini M, Boni L, Michelotti A, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015; 314: 2632-40.
 
30) Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015; 372: 923-32.
 
31) Demeestere I, Brice P, Peccatori FA, et al. No evidence for the benefit of gonadotropin-releas-ing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol. 2016; 34: 2568-74.
 
32) Leonard RCF, Adamson DJA, Bertelli G, et al. GnRH agonist for protection against ovarian tox-icity during chemotherapy for early breast cancer: The Anglo Celtic Group OPTION trial. Ann Oncol. 2017; 28: 1811-6.
 
33) Turner NH, Partridge A, Sanna G, et al. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol. 2013; 24: 2224-35.
 
34) Elgindy E, Sibai H, Abdelghani A, et al. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015; 126: 187-95.
 
35) Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormonereleasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015; 26: 2408-19.
 
36) Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016; 2: 65-73.
 
37) Lambertini M, Cinquini M, Moschetti I, et al. Temporary ovarian suppression during chemother-apy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer. 2017; 71: 25-33.
 
38) Munoz M, Santaballa A, Segui MA, et al. SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016) . Clin Transl Oncol. 2016; 18: 1229-36.
 
39) Paluch-Shimon S, Pagani O, Partridge AH, et al. Second international consensus guidelines for breast cancer in young women (BCY2) . Breast. 2016; 26: 87-99.
 
40) Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-Improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26: 1533-46.
 
41) Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 (suppl 6) : vi160-70.
 
42) National Comprehensive Cancer Network. National Comprehensive Cancer Network Guide-lines Adolescent and Young Adult (AYA) Oncology. 2017. https://www.nccn.org/professionals/physician_gls/pdf/aya.pdf
 
43) National Comprehensive Cancer Network. National Comprehensive Cancer Network Guide-lines-Breast Cancer. 2017. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
 
P.143 掲載の参考文献
1) Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013; 31: 2500-10.
 
2) 日本癌治療学会, 編. 小児, 思春期・若年性がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 東京: 金原出版; 2017.
 
3) Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fer-til Steril. 2013; 100: 1180-6.
 
4) Thomson AB, Campbell AJ, Irvine DC, et al. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. Lancet. 2002; 360: 361-7.
 
5) Shin T, Kobayashi T, Shimomura Y, et al. Microdissection testicular sperm extraction in Japa-nese patients with persistent azoospermia after chemotherapy. Int J Clin Oncol. 2016; 21: 1167-71.
 
6) Ramstein JJ, Tsai KK, Smith JF, et al. Tyrosine kinase inhibitor and male reproductive health. Clinic Pharmacol Therap. 2017; 102: 754-6.
 
7) Suzuki K, Yumura Y, Ogawa T, et al. Regeneration of spermatogenesis after testicular cancer chemotherapy. Urol Int. 2013; 91: 445-50.
 
8) Martinez G, Walscaerts M, Le Maitouard M, et al. Impact of Hodgkin or non-Hodgkin lymphoma and their treatments on sperm aneuploidy: a prospective study by the French CECOS net-work. Fertil Steril. 2017; 107: 342-50.
 
9) Bujan L, Walscaerts M, Moinard M, et al. Impact of chemotherapy and radiotherapy for testic-ular germ cell tumors on spermatogenesiss and sperm DNA: a multicenter prospective study from the CECOS network. Fertil Steril. 2013; 100: 673-80.
 
10) Rives N, Walscaerts M, Setif V, et al. Sperm aneuploidy after testicular cancer treatment: data from a prospective multicenter study performed within the French Centre d'Etude et de Con-servation des Oeufs et du Sperme network. Fertil Steril. 2017; 107: 580-8.
 
11) 第5章 生殖補助医療 12. 凍結 3) 精子凍結保存法. In: 日本生殖医学会, 編. 生殖医療の必修知識 2020. 東京: 杏林舎; 2020. p.380-2.
 
12) Takeshima T, Ueno H, Yamamoto M, et al. Sperm cryopreservation for fertility preservation in male patients with cancer at a single-center in Japan. Global Reproductive Health. 2019; 4:e34.
 
13) 湯村 寧. Onco-TESE. In: 柴原浩章, 編. 不育症・不妊症診療 その伝承とエビデンス. 東京: 中外医学社; 2019. p.580-3
 
P.149 掲載の参考文献
1) Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018; 36: 1994-2001.
 
2) Avarbock MR, Brinster CJ, Brinster RL. Reconstitution of spermatogenesis from frozen sper-matogonial stem cells. Nat Med. 1996; 2: 693-6.
 
3) Sato T, Katagiri K, Gohbara A, et al. In vitro production of functional sperm in cultured neona-tal mouse testes. Nature. 2011; 471: 504-7.
 
4) Yokonishi T, Sato T, Komeya M, et al. Offspring production with sperm grown in vitro from cryopreserved testis tissues. Nat Commum. 2014; 5: 4320.
 
5) 山中弘行, 湯村 寧, 小川毅彦. 精巣組織の凍結. Pharma Medica. 2016; 34: 31-4.
Medical*Online
6) Fayomi AP, Peters K, Sukhwani M, et al. Autologous grafting of cryopreserved prepubertal rhe-sus testis produces sperm and offspring. Science. 2019; 363: 1314-9.
 
7) Shinohara T, Inoue K, Ogonuki N, et al. Birth of offspring following transplantation of cryopre-served immature testicular pieces and in-vitro microinsemination. Hum Reprod. 2002; 17: 3039-45.
 
8) Wu X, Goodyear SM, Abramowitz LK, et al. Fertile offspring derived from mouse spermatogo-nial stem cells cryopreserved for more than 14 years. Hum Reprod. 2012; 27: 1249-59.
 
9) Wyns C, Van Langendonckt A, Wese FX, et al. Long-term spermatogonial survival in cryopre-served and xenografted immature human testicular tissue. Hum Reprod. 2008; 23: 2402-14.
 
10) Amorim CA, Curaba M, Van Langendonckt A, et al. Vitrification as an alternative means of cryo-preserving ovarian tissue. Reprod Biomed Online. 2011; 23: 160-86.
 
11) Poels J, Van Langendonckt A, Many MC, et al. Vitrification preserves proliferation capacity in human spermatogonia. Hum Reprod. 2013; 28: 578-89.
 
P.155 掲載の参考文献
1) Dursun P, Dogan NU, Ayhan A. Oncofertility for gynecologic and non-gynecologic cancers: fertility sparing in young women of reproductive age. Crit Rev Oncol Hematol. 2014; 92: 258-67.
 
2) 日本癌治療学会, 編. 総論 CQ1 挙児希望を有するがん患者に対して, どのような妊孕性に関連する情報を提供するべきか? 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 東京: 金原出版; 2017. p.22-4.
 
3) Balduzzi A, Dalle JH, Jahnukainen K, et al. Fertility preservation issues in pediatric hematopoi-etic stem cell transplantation: practical approaches from the consensus of the Pediatric Dis-eases Working Party of the EBMT and the International BFM Study Group. Bone Marrow Transplant. 2017; 52: 1406-15.
 
4) Amorim CA, Shikanov A. The artificial ovary: current status and future perspectives. Future Oncol. 2016; 12: 2323-32.
 
5) Shapira M, Raanani H, Barshack I, et al. First delivery in a leukemia survivor after transplanta-tion of cryopreserved ovarian tissue, evaluated for leukemia cells contamination. Fertil Steril. 2018; 109: 48-53.
 
6) Jensen AK, Kristensen SG, Macklon KT, et al. Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Hum Reprod. 2015; 30: 2838-45.
 
7) Dolmans MM, Marinescu C, Saussoy P, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010; 116:2908-14.
 
8) Abir R, Aviram A, Feinmesser M, et al. Ovarian minimal residual disease in chronic myeloid leu-kaemia. Reprod Biomed Online. 2014; 28: 255-60.
 
9) Dolmans M-M, Luyckx V, Donnez J, et al. Risk of transferring malignant cells with transplantedfrozen-thawed ovarian tissue. Fertil Steri. 2013; 99: 1514-22.
 
10) Kim SS, Donnez J, Barri P, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012; 29: 465-8.
 
11) Asadi-Azarbaijani B, Sheikhi M, Nurmio M, et al. Minimal residual disease of leukemia and the quality of cryopreserved human ovarian tissue in vitro. Leuk Lymphoma. 2016; 57: 700-7.
 
12) Telfer E, Torrance C, Gosden RG. Morphological study of cultured preantral ovarian follicles ofmice after transplantation under the kidney capsule. J Reprod Fertil. 1990; 89: 565-71.
 
13) Gosden RG. Restitution of fertility in sterilized mice by transferring primordial ovarian follicles. Hum Reprod. 1990; 5: 117-22.
 
14) Carroll J, Gosden RG. Physiology: transplantation of frozenthawed mouse primordial folli-cles. Hum Reprod. 1993; 8: 1163-7.
 
15) Dolmans MM, Yuan WY, Camboni A, et al. Development of antral follicles after xenografting of isolated small human preantral follicles. Reprod Biomed Online. 2008; 16: 705-11.
 
16) Vanacker J, Luyckx V, Dolmans MM, et al. Transplantation of an alginate-matrigel matrix con-taining isolated ovarian cells: first step in developing a biodegradable scaffold to transplant isolated preantral follicles and ovarian cells. Biomaterials. 2012; 33: 6079-85.
 
17) Vanacker J, Dolmans MM, Luyckx V, et al. First transplantation of isolated murine follicles in alginate. Regen Med. 2014; 9: 609-19.
 
18) Smith RM, Shikanov A, Kniazeva E, et al. Fibrin-mediated delivery of an ovarian follicle pool in a mouse model of infertility. Tissue Eng Part A. 2014; 20: 3021-30.
 
19) Kniazeva E, Hardy AN, Boukaidi SA, et al. Primordial follicle transplantation within designer bio-material grafts produce live births in a mouse infertility model. Sci Rep. 2015; 5: 17709.
 
20) Chiti MC, Dolmans MM, Orellana R, et al. Influence of follicle stage on artificial ovary outcome using fibrin as a matrix. Hum Reprod. 2015; 31: 427-35.
 
21) Rajabzadeh AR, Eimani H, Mohseni Koochesfahani H, et al. Morphological study of isolated ovarian preantral follicles using fibrin gel plus platelet lysate after subcutaneous transplanta-tion. Cell J. 2015; 17: 145-52.
 
22) Paulini F, Vilela JM, Chiti MC, et al. Survival and growth of human preantral follicles after cryo-preservation of ovarian tissue, follicle isolation and short-term xenografting. Reprod Biomed Online. 2016; 33: 425-32.
 
23) Kim J, Perez AS, Claflin J, et al. Synthetic hydrogel supports the function and regeneration of artificial ovarian tissue in mice. NPJ Regen Med. 2016; 1: 16010.
 
24) Laronda MM, Rutz AL, Xiao S, et al. A bioprosthetic ovary created using 3D printed micropo-rous scaffolds restores ovarian function in sterilized mice. Nature Communications. 2017; 8: 15261.
 
25) Cho E, Kim YY, Noh K, et al. A new possibility in fertility preservation: the artificial ovary. J Tis-sue Eng Regen Med. 2019; 13: 1294-315.
 
26) Parenteau-Bareil R, Robert G, Berthod F. Collagen-based biomaterials for tissue engineering applications. Materials. 2010; 3: 1863-87.
 
27) Dolmans MM, Martinez-Madrid B, Gadisseux E, et al. Short-term transplantation of isolated human ovarian follicles and cortical tissue into nude mice. Reproduction. 2007; 134: 253-62.
 
28) Luyckx V, Dolmans MM, Vanacker J, et al. First step in developing a 3D biodegradable fibrin scaffold for an artificial ovary. J Ovarian Res. 2013; 6: 83.
 
29) Luyckx V, Dolmans MM, Vanacker J, et al. A new step toward the artificial ovary: survival and proliferation of isolated murine follicles after autologous transplantation in a fibrin scaffold. Fertil Steril. 2014; 101: 1149-56.
 
30) Hoesli CA, Kiang RLJ, Raghuram K, et al. Mammalian cell encapsulation in alginate beads usinga simple stirred vessel. J Vis Exp. 2017; 124: 55280.
 
31) Shikanov A, Xu M, Woodruff TK, et al. A method for ovarian follicle encapsulation and culture in a proteolytically degradable 3 dimensional system. J Vis Exp. 2011; 49: 2695.
 
32) Arenas-Herrera JE, Ko IK, Atala A, et al. Decellularization for whole organ bioengineering. Biomed Mater. 2013; 8: 014106.
 
33) Laronda MM, Jakus AE, Whelan KA, et al. Initiation of puberty in mice following decellularized ovary transplant. Biomaterials. 2015; 50: 20-9.
 
34) Yoon DM, Fisher JP. Natural and synthetic polymeric scaffolds. In: Narayan R, editor. Biomed-ical Materials. Cham: Springer International Publishing; 2021. p.257-83.
 
35) Sun F, Betzendahl I, Shen Y, et al. Preantral follicle culture as a novel in vitro assay in repro-ductive toxicology testing in mammalian oocytes. Mutagenesis. 2004; 19: 13-25.
 
36) Thomas-Teinturier C, Salenave S. Endocrine sequelae after treatment of pediatric cancer: from childhood to adulthood. Bull Cancer. 2015; 102: 612-21.
 

Chapter III がん・生殖医療の課題と展望

P.160 掲載の参考文献
1) 厚生労働省. がん対策推進基本計画 (第3期) . 2018. p.51.
 
2) Pink Ring. My Story-私の選択-妊よう性温存についてのAYA世代乳がん体験者10人の物語. 2021. p.30.
 
3) Schover LR, Rhodes MM, Baum G, et al. Sisters Peer Counseling in Reproductive Issues After Treatment (SPIRIT) : a peer counseling program to improve reproductive health among Afri-can American breast cancer survivors. Cancer. 2011; 117: 4983-92.
 
P.167 掲載の参考文献
1) Desandes E, Clavel J, Berger C, et al. Cancer incidence among children in France, 1990-1999. Pediatr Blood Cancer. 2004; 43: 749-57.
 
2) Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer:a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006; 98: 890-6.
 
3) Anderson RA, Mitchell RT, Kelsey TW, et al. Cancer treatment and gonadal function: experi-mental and established strategies for fertility preservation in children and young adults. Lan-cet Diabetes Endocrinol. 2015; 3: 556-67.
 
4) Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of child-hood cancer. N Engl J Med. 2006; 355: 1572-82.
 
5) Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health out-comes in long-term survivors of childhood cancer. JAMA. 2007; 297: 2705-15.
 
6) Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an ini-tial report from the St Jude Lifetime Cohort Study (SJLIFE) . Lancet. 2017; 390: 2569-82.
 
7) Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 309: 2371-81.
 
8) Gibson TM, Mostoufi-Moab S, Stratton KL, et al. Temporal patterns in the risk of chronic healthconditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2018; 19: 1590-601.
 
P.171 掲載の参考文献
1) Centers for Disease Control and Prevention. Recommendations to improve preconception health and health care-United States. MMWR Recomm Rep. 2006; 55 (RR-06) : 1-23.
 
2) WHO. Preconception care: Maximizing the gains for maternal and child health. https://www.who.int/maternal_child_adolescent/documents/preconception_care_policy_brief.pdf
 
3) Signorello LB, Cohen SS, Bosetti C, et al. Female survivors of childhood cancer: preterm birthand low birth weight among their children. J Natl Cancer Inst. 2006; 98: 1453-61.
 
4) Reulen RC, Bright CJ, Winter DL, et al. Pregnancy and labor complications in female survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Natl Cancer Inst. 2017; 109: djx056.
 
5) van der Kooi ALF, Kelsey TW, van den Heuvel-Eibrink MM, et al. Perinatal complications in female survivors of cancer: a systematic review and meta-analysis. Eur J Cancer. 2019; 111: 126-37.
 
6) https://www.who.int/maternal_child_adolescent/documents/concensus_preconception_care/en/
 
7) Patton GC, Olsson CA, Skirbekk V, et al. Adolescence and the next generation. Nature. 2018; 554: 458-66.
 
8) 厚生労働省. 令和元年国民健康・栄養調査. 2019.
 
9) 厚生労働省. 平成30年人口動態調査. 2018.
 
10) Enomoto K, Aoki S, Toma R, et al. Pregnancy outcomes based on pre-pregnancy body mass index in Japanese women. PLoS One. 2016; 11: e0157081.
 
11) Hanson MA, Bardsley A, De-Regil LM, et al. The International Federation of Gynecology and Obstetrics (FIGO) recommendations on adolescent, preconception, and maternal nutrition: "Think Nutrition First". Int J Gynaecol Obstet. 2015; 131 (Suppl 4) : S213-53.
 
P.174 掲載の参考文献
1) Gardino SL, Jeruss JS, Woodruff TK. Using decision trees to enhance interdisciplinary team work: the case of oncofertility. J Assist Reprod Genet. 2010; 27: 227-31.
PubMed
2) Ito Y, Sugimoto K, Suzuki N, et al. The utility of decision trees in oncofertility care in Japan. J Adolesc Young Adult Oncol. 2017; 6: 186-9.
 
3) Shiraishi E, Sugimoto K, Suzuki N, et al. Study of the awareness of adoption as a family-build-ing option among oncofertility stakeholders in Japan. J Glob Oncol. 2018; 4: 1-7.
 
4) Sugimoto K, Anami R, Suzuki N, et al. A study of the criteria for young cancer survivors to become foster or adoptive parents in Japan. 日生殖心理会誌. 2018; 4: 12-9.
 
5) 杉本公平, 小泉智恵, 岡田 弘, 他. 里親制度・特別養子縁組に関する情報提供の現状～埼玉県里親会でのアンケート調査～. 日生殖心理会誌. 2020; 6: 1: 38-43.
 
P.177 掲載の参考文献
1) Suzuki N. Clinical practice guidelines for fertility preservation in pediatric, adolescent, and young adults with cancer. Int J Clin Oncol. 2019; 24: 20-7.
 
2) Furui T, Takenaka M, Makino H, et al. An evaluation of the Gifu Model in a trial for a new regional oncofertility network in Japan, focusing on its necessity and effects. Reprod Med Biol. 2015; 15: 107-13.
 
3) 原 鐵晃, 頼 英美, 植田 彩, 他. がん・生殖医療ネットワークの展開・広島での取り組み. 日がん・生殖医療会誌. 2018; 1: 27-34.
 
4) 木村文則. 滋賀がん・生殖医療ネットワーク構築と運営. 日小児血がん会誌. 2018; 55: 133-5.
Medical*Online
5) 堀江昭史, 谷 洋彦, 万代昌紀, 他. がん・生殖医療ネットワーク: 京都府における試み. 日がん・生殖医療会誌. 2018; 1: 35-9.
 
6) 竹中基記, 古井辰郎, 鈴木 直, 他. がん・生殖医療連携未整備地域24か所の現状と課題-地域格差を解消するための施策-. 癌と化療. 2020; 47: 1691-6.
Medical*Online
7) 高井 泰. 世界のがん・生殖医療とわが国の補助金制度・登録制度の取り組み. 産と婦. 2019; 86: 411-6.
Medical*Online
P.180 掲載の参考文献
1) Callahan ST, Winitzer RF, Keenan P. Transition from pediatric to adult-oriented health care: a challenge for patients with chronic disease. Curr Opin Pediatr. 2001; 13: 310-6.
 
2) Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018; 60: 4-12.
PubMed
3) Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of child-hood cancer. N Engl J Med. 2006: 355; 1572-82.
 
4) Chao C, Bhatia S, Xu L, et al. Chronic comorbidities among survivors of adolescent and young adult cancer. J Clin Oncol. 2020; 38: 3161-74.
 
5) 日本癌治療学会, 編. 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン. 2017年度版. 東京: 金原出版; 2017. p.94-112.
 
6) 日本小児科学会移行期の患者に関するワーキンググループ. 小児期発症疾患を有する患者の移行期医療に関する提言. www.jpeds.or.jp/modules/guidlines/index.php?content_id=54
 
7) 江口泰正. 健康教育の新しいキーワードとしてのヘルスリテラシー. 日栄養士会誌. 2018; 61: 557-65.
 
8) 国立成育医療研究センター小児がんセンター, 編. 小児がん経験者のためのトランジション・ステップ. https://www.ncchd.go.jp/hospital/about/section/cancer/leaflet06.pdf
 
P.183 掲載の参考文献
1) von Wolff M, Montag M, Dittrich R, et al. Fertility preservation in women--a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011; 284: 427-35.
 
2) Germeyer A. Registerdaten 2015 Fertiprotekt. 2016. https://static1.squarespace.com/static/560a328fe4b0e8c4f373857e/t/57206c853c44d81ea19e790b/1461742728020/registerdaten_fertiprotekt_2015.pdf.
 
3) Anazodo AC, Stern CJ, McLachlan RI, et al. A study protocol for the Australasian Oncofertility Registry: monitoring referral patterns and the uptake, quality, and complications of fertilitypreservation strategies in Australia and New Zealand. J Adolesc Young Adult Oncol. 2016;5: 215-25.
 
4) Anazodo AC, Gerstl B, Stern CJ, et al. Utilizing the experience of consumers in consultation todevelop the Australasian Oncofertility Consortium Charter. J Adolesc Young Adult Oncol. 2016; 5: 232-9.
 
5) Moravek MB, Appiah LC, Anazodo A, et al. Development of a pediatric fertility preservation program: a report from the pediatric initiative network of the oncofertility consortium. J Ado-lesc Health. 2019; 64: 563-73.
 
6) 高井 泰. 世界のがん生殖医療とわが国の補助金制度, 登録制度の取り組み. 産と婦. 2019; 86: 411-6.
 
7) 高井 泰. ドイツ・スイスおよびオーストラリアにおける若年がん患者に対するがん・生殖医療の実際-わが国として学ぶべきものは? 日がん・生殖医療会誌. 2018; 1: 40-4.
 
8) 重松幸佑, 高井 泰. 日本がん・生殖医療登録システム (JOFR) の現状と課題. 日がん・生殖医療会誌. 2021; 4: 46-51.
 
9) Yumura Y, Tsujimura A, Okada H, et al. Current status of sperm banking for young cancer patients in Japanese nationwide survey. Asian J Androl. 2018; 20: 336-41.
 
10) Sanada Y, Harada M, Kunitomi C, et al. A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients. J Obstet Gynaecol Res. 2019; 45: 2021-8.
 
11) 日本産科婦人科学会. 医学的適応による未受精卵子, 胚 (受精卵) および卵巣組織の凍結・保存に関する見解. 2019. http://www.jsog.or.jp/modules/statement/index.php?content_id=23.
 
12) 日本産科婦人科学会. 精子の凍結保存に関する見解. 2007. http://www.jsog.or.jp/modules/statement/index.php?content_id=26.
 
13) 日本生殖医学会. 精子の凍結保存について. 2006. http://www.jsrm.or.jp/guideline-statem/guideline_2006_02.html
 
P.186 掲載の参考文献
1) 高井 泰. ドイツ・スイスおよびオーストラリアにおける若年がん患者に対するがん・生殖医療の実際 わが国として学ぶべきものは? 日がん・生殖医療会誌. 2018; 1: 40-4.
 
2) 洞下由記, 清水千佳子, 古井辰郎, 他. 47都道府県におけるがん・生殖医療に関わる公的助成金制度構築に関する実態調査-小児・AYA世代がん患者における生殖機能温存医療支援体制の必要性について. 日がん・生殖医療会誌. 2021; 4: 39-45.
 
P.188 掲載の参考文献
1) 日本癌治療学会, 編. 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 東京: 金原出版; 2017.
 
2) 日本医療研究開発機構 (AMED) 革新的がん医療実用化研究事業 生殖機能温存がん治療法の革新的発展にむけた総合的プラットフォームの形成研究班 (代表 大須賀穣) , 編. がん患者の妊孕性温存のための診療マニュアル. 東京: 金原出版; 2019.
 
3) Kunitomi C, Harada M, Sanada Y, et al. The possible effects of the Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 on the practice of fertility preservation in female cancer patients in Japan. Reprod Med Biol. 2022; 21: e12453.
 

書評

最近チェックした商品履歴

Loading...